Elevated levels of preβ1-high-density lipoprotein are associated with cholesterol ester transfer protein, the presence and severity of coronary artery disease

Lipids in Health and Disease

Volumn 16, Issue 1, 2017, Pages 1-7

  Bu, Xiao min ^a   Niu, Dong mei ^a   Wu, Jia ^a   Yuan, Yun long ^a   Song, Jia xi ^a   Wang, Jun jun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; CETP; Coronary artery disease; Pre 1 HDL

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; PRE BETA 1 HIGH DENSITY LIPOPROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CETP PROTEIN, HUMAN; LIPID;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENSINI SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE LINEAR REGRESSION ANALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; STABLE CORONARY ARTERY DISEASE; STENOSIS; BLOOD; CASE CONTROL STUDY;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85008965853     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0394-1     Document Type: Article

References (41)

1. Mendivil CO, Furtado J, Morton AM, Wang L, Sacks FM. Novel pathways of apolipoprotein A-I metabolism in high-density lipoprotein of different Sizes in Humans. Arterioscler Thromb Vasc Biol. 2016;36:156-65.
2. Miida T, Obayashi K, Seino U, Zhu Y, Ito T, Kosuge K, et al. LCAT-dependent conversion rate is a determinant of plasma prebeta1-HDL concentration in healthy Japanese. Clin Chim Acta. 2004;350:107-14.
3. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol. 2009;16:163-71.
4. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res. 2004;45:1967-74.
5. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
6. Miida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, et al. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2000;20:2428-33.
7. Miida T, Miyazaki O, Hanyu O, Nakamura Y, Hirayama S, Narita I, et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol: JASN. 2003;14:732-8.
8. Hirayama S, Miida T, Miyazaki O, Aizawa Y. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care. 2007;30:1289-91.
9. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab. 2008;10:476-83.
10. Guey LT, Pullinger CR, Ishida BY, O’Connor PM, Zellner C, Francone OL, et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol. 2011;108:360-6.
11. Chen Y, Dong J, Chen X, Jiang H, Bakillah A, Zhang X, et al. Human serum prebeta1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases. Nutr Metab. 2016;13:36.
12. Tosheska K, Labudovic D, Jovanova S, Jaglikovski B, Alabakovska S. Cholesteryl ester transfer protein, low density lipoprotein particle size and intima media thickness in patients with coronary heart disease. Bosn J Basic Med Sci. 2011;11:169-73.
13. Scharnagl H, Heuschneider C, Sailer S, Kleber ME, Marz W, Ritsch A. Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. Eur J Clin Invest. 2014;44:395-401.
14. Rashid S, Sniderman A, Melone M, Brown PE, Otvos JD, Mente A, et al. Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. Eur J Prev Cardiol. 2015;22:468-77.
15. Francone OL, Royer L, Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res. 1996;37:1268-77.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
17. Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med. 2015;47:386-93.
18. Miida T, Miyazaki O, Nakamura Y, Hirayama S, Hanyu O, Fukamachi I, et al. Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J Lipid Res. 2003;44:645-50.
19. Wang J, Zhuang Y, Lui X, Li Y, Qiang H. Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. Clin Chim Acta. 2001;305:19-25.
20. Wang J, Gu Q, Li K, Zhang C. CETP and oxidized LDL levels increase in dyslipidemic subjects. Clin Biochem. 2007;40:995-9.
21. Wang JJ, Gong JB, Li HQ, Niu DM, Han AZ, Wu J, et al. Lipoprotein(a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb. 2012;19:81-9.
22. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Biochem. 2010;56:1128-37.
23. Tashiro J, Miyazaki O, Nakamura Y, Miyazaki A, Fukamachi I, Bujo H, et al. Plasma pre beta1-HDL level is elevated in unstable angina pectoris. Atherosclerosis. 2009;204:595-600.
24. Tian L, Li C, Liu Y, Chen Y, Fu M. The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome. PLoS One. 2014;9:e85114.
25. Miyazaki O, Kobayashi J, Fukamachi I, Miida T, Bujo H, Saito Y. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J Lipid Res. 2000;41:2083-8.
26. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study. Arterioscl Throm Vas. 2004;24:2181-7.
27. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL intervention trial. Arterioscl Throm Vas. 2005;25:2185-91.
28. van Tienhoven-Wind LJ, Perton FG, Dullaart RP. Pre-beta-HDL formation relates to high-normal free thyroxine in type 2 diabetes mellitus. Clin Biochem. 2016;49:41-6.
29. Kane JP, Malloy MJ. Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol. 2012;23:367-71.
30. Rohatgi A, Grundy SM. Cholesterol Efflux capacity as a therapeutic target: rationale and clinical implications. J Am Coll Cardiol. 2015;66:2211-3.
31. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci. 2005;62:2150-60.
32. Samyn H, Moerland M, van Haperen R, Grosveld F, van TOL A, et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009;204:429-34.
33. Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E, et al. Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscl Thromb Vasc Biol. 2012;32:2341-9.
34. Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care. 2002;5:153-8.
35. Gonzalez-Pacheco H, Amezcua-Guerra LM, Vazquez-Rangel A, Martinez-Sanchez C, Perez-Mendez O, Verdejo J, Bojalil R. Levels of high-density lipoprotein cholesterol are associated with biomarkers of inflammation in patients with acute coronary syndrome. Am J Cardiol. 2015;116:1651-7.
36. Miida T, Ozaki K, Murakami T, Kashiwa T, Yamadera T, Tsuda T, et al. Prebeta1-high-density lipoprotein (prebeta1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP). Clin Chim Acta. 2000;292:69-80.
37. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res. 1992;33:1807-16.
38. Sugano M, Makino N, Yanaga T. Effects of hepatic HDL-related mRNAs on plasma prebeta HDL in cholesterol-fed rabbits. Artery. 1997;22:182-205.
39. Miida T, Yamaguchi T, Tsuda T, Okada M. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis. 1998;138:129-34.
40. Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol. 2015;66:2201-10.
41. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia. 2005;48:1105-13.